Stock info Arca Biopharma | Filter  Basic-Info

Arca Biopharma

The past year was a good year for Arca Biopharma investors

The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 44 percent. Over the period 2011-2016 the stock lost a massive -66,67 percent. Arca Biopharma's net incomes between 2011 and 2015 were very volatile through the time and moved between -5,36 million dollars and -11,45 million dollars.

Arca Biopharma's head office is located in Westminster. Arca Biopharma's core business is the biotech sector. The global biotech companies gained around 59 percent over the period 2006-2016. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The American company didn't pay out any dividends (in the past 5 years).

Arca Biopharma financed with relatively a lot of debt

At the end of 2015 the American company had a balance sheet of 39,57 million dollars. Last year the total debt of the company was 1,5 million dollars. This equals around 3,79 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around -4. So investors paid -4 times the company's 2015's EPS. Based on the classical stock valuation theories the American stock can be seen as a value stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 29,25 million dollars. At the end of 2015 around 6,29 million stocks were listed.

All Arca Biopharma's annual reports can be found here. More information about Arca Biopharma can be found it's website. .